Aging Blockbusters And Pricing Pressures Will Erode Profitability

Key Takeaways

• Heavy dependence on aging therapies and patent expirations exposes Amgen to revenue and margin declines amid increasing biosimilar and innovative competition.
  
• Regulatory and pricing pressures, combined with acquisition integration risks and escalating costs, may restrict profitability and challenge sustainable long-term growth.
  
• Expanding product pipeline, operational efficiencies, and secular healthcare trends position Amgen for sustained revenue growth, greater earnings resilience, and improved long-term profitability.

Catalysts

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

• The company faces mounting pressure from prospective drug pricing reforms and the progressive adoption of value-based care models, which are likely to constrain its pricing power and limit long-term revenue growth as payors become less willing to reimburse for expensive branded therapies.
  
• Despite strong short-term volume growth, Amgen's overreliance on aging blockbuster drugs such as Enbrel, combined with looming patent cliffs and accelerating biosimilar competition in both core and emerging markets, threatens significant revenue erosion and gross margin compression over time.
  
• The growing risk of government-imposed price controls or reference pricing, particularly in the U.S. and key international markets, may act as a cap on future profitability, placing long-term limitations on both earnings expansion and free cash flow generation.
  
• Intensifying competition from innovative biotech and large pharmaceutical companies-with novel modalities including gene therapies, mRNA treatments, and next-generation obesity drugs (including orally delivered GLP-1s)-poses a risk to Amgen's future market share, slowing the ramp-up of new products and leading to potential stagnation or contraction in top-line growth.
  
• Large-scale acquisitions such as Horizon Therapeutics introduce the potential for integration challenges and increased operational leverage, which, when coupled with sharply rising R&D and capital expenditures, could strain net margins and shareholder returns if new product launches fail to offset pressures from patent expirations and deteriorating pricing environments.

Amgen Future Earnings and Revenue Growth

Assumptions

• This narrative explores a more pessimistic perspective on Amgen compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Amgen's revenue will decrease by 0.3% annually over the next 3 years.
• The bearish analysts assume that profit margins will shrink from 19.0% today to 15.6% in 3 years time.
• The bearish analysts expect earnings to reach $5.4 billion (and earnings per share of $9.98) by about August 2028, down from $6.6 billion today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 27.5x on those 2028 earnings, up from 23.4x today. This future PE is greater than the current PE for the US Biotechs industry at 13.2x.
• Analysts expect the number of shares outstanding to grow by 0.19% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.21%, as per the Simply Wall St company report.

Amgen Future Earnings Per Share Growth

Risks

• Amgen is experiencing strong, broad-based volume and revenue growth across multiple therapeutic areas, including double-digit sales growth for 15 products and a 9% year-over-year increase in total revenue, which may drive further top-line and earnings expansion.
  
• The company's robust late-stage pipeline-including promising assets in obesity (MariTide), rare diseases, cardiovascular medicine, oncology, and a strong bispecific T cell engager (BiTE) platform-positions Amgen for meaningful new product launches, supporting long-term revenue diversification and profit growth.
  
• Strategic focus and leading execution in biosimilars, as evidenced by 40% year-over-year sales growth and a successful track record in launches and regulatory approvals, could significantly bolster Amgen's revenues and improve operational margins as more high-revenue biologics lose patent protection.
  
• Ongoing investments in artificial intelligence, automation, and R&D, paired with disciplined financial management, are driving greater operating efficiency and free cash flow, which could underpin resilient net margins and long-term profitability.
  
• Secular trends such as an aging global population, rising prevalence of chronic and rare diseases, and expanding demand for personalized and biologic medicines provide enduring tailwinds, likely increasing utilization of Amgen's portfolio and supporting long-term revenue and earnings growth.

Valuation

• The assumed bearish price target for Amgen is $222.44, which represents two standard deviations below the consensus price target of $315.0. This valuation is based on what can be assumed as the expectations of Amgen's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $405.0, and the most bearish reporting a price target of just $185.0.
  
• In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $34.6 billion, earnings will come to $5.4 billion, and it would be trading on a PE ratio of 27.5x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $288.23, the bearish analyst price target of $222.44 is 29.6% lower.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.